Polidocanol sclerotherapy of pharyngx for obstructive sleep apnea (OSA) and snoring subjects(SS)

Phase 1

• Conditions: Obstructive sleep apnea syndrome (OSAS); Snoring subjects (SS); Respiratory - Sleep apnoea

• Registration Number: ACTRN12606000444583
• Lead Sponsor: Youliang Yin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-10-17
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

OSAS & ,SS which palatopharyngeal collapse.

Exclusion Criteria

Obstructive sleep apnea syndrom (OSAS) & snoring subjects (SS),which anatomic narrow result.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Apnea-hypopnea index (AHI) in 2 years.<br><br>AHI is on polysomnography (PSG), to compare AHI anterior (1 time) and posterior treatment (3 times).[Each patient with osas must be carried out PSG for 4 times.One time is before treatment, the others times are in 1/2, 1 and 2 years after treatment.];Anterior-posterior treatment in 2 years.<br><br>AHI is on polysomnography (PSG), to compare AHI anterior (1 time) and posterior treatment (3 times).[Each patient with osas must be carried out PSG for 4 times.One time is before treatment, the others times are in 1/2, 1 and 2 years after treatment.]

Secondary Outcome Measures

Name	Time	Method
Arterial oxygen saturation (SaO2) and body mass index (BMI) will be measured on polysomnography (PSG), to compare the lowest SaO2 of anterior - posterior treatment and variation of BMI.[]